SOURCE: Entest BioMedical Inc.

November 23, 2010 10:00 ET

Entest BioMedical Chairman Discusses Anticipated Short Range and Mid-Range Milestones

Milestones to Include: Veterinary Clinic Acquisitions, Near Term Revenue, and ImenVax™ Safety Study

SAN DIEGO, CA--(Marketwire - November 23, 2010) -  Entest BioMedical Inc. (OTCBB: ENTB) Chairman & CEO David Koos covered Entest's short range and mid-range milestones. These Company milestones include acquisitions of veterinary clinics, the ImenVax™ Safety Study and the generation of near term revenue.

David Koos stated, "Entest is currently in the process of acquiring its first veterinary clinic. I see this as both a source of near term revenue and further out it should serve as part of our distribution channel for veterinary therapeutics under development. It is the Company's goal to acquire between 5 to 10 veterinary clinics over the next 12 months with a targeted revenue stream of $3.5 million to $7 million. Two of the clinics we have identified as potential acquisitions historically have treated approximately 1,400 dogs per year with cancer. If ImenVax™ were currently available, these dogs could potentially be treated with this cancer vaccine. We are extremely excited about the use of clinics as potential distribution channels for our therapeutic products and services."

"Currently, Entest is preparing to begin its ImenVax™ Safety Study," stated Mr. Koos. "We believe that once we complete this study, which should take between 6 to 9 months, we should demonstrate not only that our immuno-therapeutic cancer vaccine for dogs is safe but also has a level of efficacy that allows us to proceed with using this vaccine for treating dogs with cancer. Once ImenVax™ I is available for use, our scientific consultants will proceed with some refinements in ImenVax™ II that could make this vaccine even more robust. These refinements will most likely be 2 to 3 years out after ImenVax™ I is available for use."

A spokesperson for the Company noted once it has acquired 10 veterinary clinics, Entest should be able to self fund its research from the revenue these veterinary clinics generate. This ability to self fund research should give Entest a leg up on other companies using more traditional funding models.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information